





Q Therapeutics, Inc.

www.qthera.com

Investor Fact Sheet | August 2014

Headquartered in Salt Lake City, Utah, Q Therapeutics is developing adult stem cell therapies to treat debilitating diseases of the Central Nervous System (CNS). The Company has 20 patents (plus many pending) protecting its underlying intellectual property through 2030. Q Therapeutics is applying this new platform technology to treatment of Amyotrophic Lateral Sclerosis (ALS, or Lou Gehrig's Disease), Transverse Myelitis, Multiple Sclerosis and Spinal Cord Injury. Future indications may include Stroke, Traumatic Brain Injury, and Huntington's, Parkinson's and Alzheimer's diseases.



Q Therapeutics harnesses the power of adult stem cells, using proven natural support and repair systems of the healthy central nervous system (CNS). In many diseases, damage and destruction of support cells (Glia) of the CNS leads to loss of function and death of the neurons. The Company's first patented product, *Q-Cells*®, is a cell-based therapeutic intended to restore or preserve the normal activity of neurons by providing essential support functions that occur in healthy CNS tissues. *Q-Cells* are healthy human glial cells. The role of glial cells in the brain and spine is to support and protect neurons, which form the signal transmission lines of the CNS. Q Therapeutics' has been the beneficiary of grant funding of over \$4 million, including from the National Institutes of Health, to develop *Q-Cells* technology for treatment of ALS. In addition, Cephalon/Teva (Nasdaq:TEVA) has made a \$3.7 million equity investment in the Company providing further validation and support of its research and development efforts.

WHY INVEST IN Q THERAPEUTICS?

- Differentiated approach | developing cell-based therapies for neurodegenerative disease | few competitors
- Addresses significant medical need and billion dollar commercial opportunities
- Progressing toward IND filing later this year for ALS
- In Q313, *QCells* product was granted Orphan Drug designation by FDA for treatment of ALS
- Validated by Pharma: \$3.7 million investment by Cephalon/Teva
- Validated by peer review: NIH grant funding for ALS: \$4 Million; scientific publications
- Very strong patent estate protecting unique products, use and manufacturing
- World class leadership and board of directors

Q Therapeutics, Inc.

Corporate Headquarters:
615 Arapeen Drive, #102
Salt Lake City, Utah 84108
Phone: 801-582-5400
Web: www.qthera.com

Investor Relations:

Hanover|Elite
Phone: 407-585-1080
QCEL@hanoverelite.com

Management:

Deborah A. Eppstein, PhD
President & CEO
Steven J. Borst
CFO & VP, Corporate Development
Mahendra Rao, MD, PhD
CSO & Chairman of Scientific Advisory Board
James Campanelli, PhD
Vice President, Research & Development

Board of Directors:


Deborah A. Eppstein, PhD
Peter Grebow, PhD
Peter Barton Hutt, Esq
Diane Jorkasky, MD
Dinesh Patel, PhD, Chairman
Linda F. Powers, Esq



Q Therapeutics, Inc.

www.qthera.com

Investor Fact Sheet | August 2014



Q-Cells: First Clinical Product Multiple Indications

IND Submission				
Late Pre-Clinical				
Early Pre-Clinical				
Manufacturing				
Indication	ALS	Transverse Myelitis	Spinal Cord Injury	Stroke

Safety and manufacturing data obtained in ALS pre-clinical studies may also support IND filings for TM and SCI, providing significant cost and time savings per indication

* Subject to securing necessary financing and regulatory clearances

Attributes of Q-Cells® The Workhorses of the CNS

- Normal cells, normal function, natural *environment*
- Produce Astrocytes & Oligodendrocytes, not unwanted cell types (neurons)
- Proven support & repair mechanisms of healthy CNS
- Provide neuroprotection and myelination, enabling treatment of a wide range of disease targets
- Cells migrate & expand within CNS – fewer cells and injection sites required
- Cells remain in CNS – more cells at target sites; reduces off-target effects
- No toxicity observed in >200 animals in six independent labs
- Activity in five neurodegenerative disease models
- Cost effective, readily scalable manufacturing

Market Snapshot

Shares Outstanding:	30,296,726
Estimated Public Float:	N/A
Market Capitalization:	N/A
52-Week Low/High:	N/A-N/A
Fiscal Year End:	December 31
Cash (as of 6-30-14):	\$1,400,867

Addressing High Growth Market Opportunity

The global market for stem cell therapy was \$3.8 billion in 2011 and is expected to reach \$6.6 billion by 2016.*

Central Nervous System cell therapy products are a rising sector with few competitors.

*Source: "Global Markets for Stem Cells" ReportsnReports | July 2012

Recent News

7/7/14: Q Therapeutics Announces First U.S. Patent Relating To Fifth Patent Family On Neural Cells

6/9/14: Q Therapeutics To Present At NIBA's 131st Investment Conference

4/21/14: Q Therapeutics Issues Formal Corporate Update

4/1/14: Mahendra Rao, MD, PhD Rejoins Q Therapeutics as Chief Strategy Officer

1/8/14: Q Therapeutics to Present at Biotech Showcase™ 2014 to Be Held During JP Morgan Healthcare Conference in San Francisco

Any statements contained in this document that refer to future events or other non-historical facts are forward-looking statements that reflect Q Therapeutics' ("the Company" or "Q") current perspective of existing trends and information as of the date of this document. Except as expressly required by law, the Company disclaims any intent or obligation to update these forward-looking statements. Actual results may differ materially from Q's current expectations depending upon a number of factors affecting the Company's business. These factors include, among others, the difficulty of predicting the timing or outcome of product development efforts and FDA or other regulatory agency approvals or actions, if any; availability and pricing of third-party-sourced products and materials; successful compliance with FDA and other governmental regulations applicable to Q's products and/or businesses; and other risks and uncertainties detailed in the Company's periodic public filings with the Securities and Exchange Commission, including but not limited to the Company's Form 10-Q for the quarter ended June 30, 2014.